Emergent Biosolutions
EBS
210 hedge funds and large institutions have $852M invested in Emergent Biosolutions in 2022 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 79 increasing their positions, 70 reducing their positions, and 47 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 70
0.31% more ownership
Funds ownership: 81.15% → 81.45% (+0.31%)
9% less funds holding
Funds holding: 231 → 210 (-21)
12% less call options, than puts
Call options by funds: $1.78M | Put options by funds: $2.01M
33% less capital invested
Capital invested by funds: $1.28B → $852M (-$426M)
38% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 47
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
+$18.2M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$15.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$11.6M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$10.6M |
| 5 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$7.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EARNEST Partners
Atlanta,
Georgia
|
-$57.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$13.9M |
| 3 |
Morgan Stanley
New York
|
-$10.4M |
| 4 |
Millennium Management
New York
|
-$9.64M |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
-$8.39M |
EBS Hedge Fund Activity: Q3 2022 in Review
210 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q3 2022, worth a combined $852M — down 33% from $1.28B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of EBS and 29 opened new positions — a net loss of 18 holders — while 70 trimmed existing stakes and 79 added.
The largest buyer was Man Group, opening a new position worth an estimated $18.2M. The largest seller was EARNEST Partners, exiting entirely with an estimated $57.3M sold.
- 210 institutional investors held Emergent Biosolutions (EBS) as of Q3 2022, down from 231 in Q2 2022.
- Funds reported $852M of Emergent Biosolutions stock for Q3 2022, down 33% quarter-over-quarter.
- 29 funds opened new Emergent Biosolutions positions in Q3 2022 and 47 closed out, a net change of -18 holders.
- The largest Emergent Biosolutions buyer in Q3 2022 was Man Group, an estimated $18.2M added.
- The largest Emergent Biosolutions seller in Q3 2022 was EARNEST Partners, an estimated $57.3M sold.
Based on aggregated 13F filings for Q3 2022.